Abstract 4664: Result of TORI L-03, a randomized, multicenter phase II clinical trial of erlotinib (E) or E + fulvestrant (F) in previously treated advanced non-small cell lung cancer (NSCLC).
Year: 2013
Type: conference-abstract
Source: Cancer Research
Authors: Edward B. Garon, Jill M. Siegfried, Steven M. Dubinett, Robert M. Elashoff, David J. Park, Rupesh J. Parikh, Ravi Patel, Eddie H. Hu, Karen L. Reckamp, Brad Adams, Diego Martinez, He-Jing Wang, Fairooz Kabbinavar, Sanja Dacic, Meghan Brennan, Isett Laux, Diana C. Marquez-Garban, Laura P. Stabile, Dennis J. Slamon, Richard J. Pietras
Institutions: University of California, Los Angeles, UPMC Hillman Cancer Center, St. Jude Medical Center, Comprehensive Cancer Centers of Nevada, Comprehensive Blood & Cancer Center, Hematology Oncology Associates of Central New York, New York Oncology Hematology, Asociación Colombiana de Hematología y Oncología, City Of Hope National Medical Center
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2020650459